Article
Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases.
Clinical and experimental dermatology - 1 Oct 2022
Alfallouji Yasmin, Spencer Ashley, Calonje Eduardo, Perrett Conal M, Watchorn Richard, Borysiewicz Catherine, Hodgkinson Tara, Wasan Harpreet, Bunker Christopher B, Sidwell Rachel U
Abstract excerpt
Encorafenib is a BRAF inhibitor increasingly used as a second-line treatment for metastatic melanoma and colorectal cancer. BRAF inhibitors have been reported to be associated with new and changing melanocytic lesions, including eruptive naevi. We describe two cases of eruptive naevi secondary to encorafenib used for the treatment of BRAF-mutant metastatic colorectal cancer.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.